Affiliation:
1. N.I.Pirogov Russian National Research Medical University (RNRMU); “Medicinа”
2. N.I.Pirogov Russian National Research Medical University (RNRMU)
3. “Medicinа”
Abstract
Breast cancer (BC) remains one of the most common diseases of the female population. According to statistics, breast cancer is detected in every eighth woman. Approximately 20‑24% of breast cancer patients are diagnosed with triple negative breast cancer. Triple‑negative breast cancer is characterized by an aggressive clinical course, a higher relapse rate, and low overall survival. According to statistics, the median survival rate for women with metastatic triple‑negative breast cancer is less than one year. We demonstrate a successful case of treatment of a 60‑year‑old woman diagnosed with triple negative breast cancer on the right, edematous‑infiltrative form, St IIIC cT4bN3M0 on the background of metabolic syndrome. Antitumor treatment lasted 1 year and consisted of three stages: systemic chemotherapy, surgical treatment (radical mastectomy), and adjuvant radiation therapy. After the treatment, remission was achieved. The patient is alive and has a relapse‑free period of 3 years. Conclusion. Despite the severe concomitant pathology in the observed patient, we received a positive result of multi‑ stage therapy, where cytotoxic chemotherapy was the basic treatment for a woman with triple negative breast cancer.
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference22 articles.
1. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol. 2018 Jun;25(Suppl 1):S142–S150. https://doi.org/10.3747/co.25.3954
2. Roytberg GE, Kondratova NV. Screening and prophylaxis of breast cancer in primary care. Vestnik Roszdravnadzora. 2018;1:57–61. (In Russian).
3. Astashov VV, Volkova MS, Kazakov OV, Ivanova EB, Larionov PM, CHepik VI, et al. Regional lymphatic bed in experimental induction of breast cancer in the conditions of preventive phytotherapy. A life without danger. Health. Prevention. Longevity. 2012;7(2):109–115. (In Russian).
4. Vladimirova LYu, Storozhakova AE, Snezhko TA, Strakhova LK, Abramova NA, Kabanov SN, et al. Hormone-positive HER2-negative metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46–51. (In Russian). https://doi.org/10.37748/2687-0533-2020-1-2-6
5. Jhan J-R, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017 Nov;18(17):1595–1609. https://doi.org/10.2217/pgs-2017-0117
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献